Glen Barber named director of Center for Innate Immunity and Inflammation at Ohio State’s Pelotonia Institute for Immuno-Oncology

LifeCare Alliance, Ohio State collaborate to advance cancer health equity

LifeCare Alliance and the Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Center and Richard J. Solove Research Institute announced a partnership aimed at enhancing access to breast cancer screening and diagnostics for underserved individuals across Ohio.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Vaping and smoking together increases lung cancer risk fourfold

People who both vape and smoke are four times more likely to develop lung cancer than people who just smoke, according to a new study published by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and College of Public Health.

August 02, 2024

Vol.50 No.31

In Brief

Linda Liau elected to Taiwan’s Academia Sinica

Linda Liau, chair of neurosurgery at the David Geffen School of Medicine at UCLA, was elected as an Academician of Academia Sinica by the 35th Convocation of Academicians, the preeminent academic institution in Taiwan.

July 12, 2024

Vol.50 No.28

Clinical Roundup

CHK1 inhibitor + rheumatoid arthritis drug could be therapy for NSCLC

The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute researchers have found a potentially effective drug-combination approach to treating certain patients with non-small cell lung cancer.

June 28, 2024

Vol.50 No.26

In Brief

Christian Rolfo named director of Ohio State Division of Medical Oncology

Christian Rolfo was named director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. He will start on Aug. 15.

June 21, 2024

Vol.50 No.25

Clinical Roundup

NLRC5 is an innate immune sensor that plays a crucial role in PANoptotic cell death

NLRC5 plays a previously unknown role as an innate immune sensor, triggering cell death, according to new research from St. Jude Children’s Research Hospital. The findings, published in Cell, show how NLRC5 drives PANoptosis, a prominent type of inflammatory cell death.

June 21, 2024

Vol.50 No.25

Glen Barber named director of Center for Innate Immunity and Inflammation at Ohio State’s Pelotonia Institute for Immuno-Oncology

YOU MAY BE INTERESTED IN

LifeCare Alliance, Ohio State collaborate to advance cancer health equity

Vaping and smoking together increases lung cancer risk fourfold

Linda Liau elected to Taiwan’s Academia Sinica

CHK1 inhibitor + rheumatoid arthritis drug could be therapy for NSCLC

Christian Rolfo named director of Ohio State Division of Medical Oncology

NLRC5 is an innate immune sensor that plays a crucial role in PANoptotic cell death

Renew today!

Subscriber content

Login